Key facts
- Myconeos’s last known valuation is $3.6M (Mar 2025).
- It has raised $1.0M; the latest was Out of Business in Dec 2025.
- Status: Out of Business.
- ·Watchlist + deal alerts for Myconeos
- ·The full record, as it builds
Funding rounds
No funding rounds for Myconeos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myconeos
Developer of natural, biologically-derived microbial strains designed for use in food fermentation processes. The company's technology isolates and breeds, sells, and licenses fungal strains to produce novel cultures with properties, such as new strains for traditional and plant-based protein applications enabling food producers to create differentiated fermented products with improved consistency, reduced waste, and expanded innovation potential across traditional markets and the growing plant-based alternatives market.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2018
- Employees
- 6
- Website
- myconeos.com/
- Ownership
- Out of Business
Myconeos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myconeos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myconeos in its N-PORT filings yet. We sweep new filings monthly.